$GLMD News

Galmed Reports Preclinical Results for Heart Disease Drug Combination, Study Identifies New Pathway Linked to Cardiac Fibrosis

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed Pharmaceuticals Announces Milestone Results From Phase 1 PK Study In Healthy Subjects; 400mg AM Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid 300mg

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Pharmaceuticals Partners With Ramot At Tel Aviv University To Evaluate Aramchol As Targeted Therapy For Metastatic Brain Cancer

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Stock Soars On Brain-Penetrating Aramchol Formulation

Galmed Pharmaceuticals shares are trading higher after the company announced the development of a brain penetrating new formulation of Aramchol.

Galmed Pharmaceuticals shares are trading higher after the company announced the development of a brain penetrating new formulation of Aramchol.

Galmed Pharmaceutical And Barcode Nanotech Develop Novel Aramchol Formula That Penetrates The Blood-Brain Barrier To Deliver Parkinson's And Dementia Medications

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Pharmaceuticals Presents Late-Breaking Abstract At HEP-DART 2025 Meeting

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis